Physician profile
Bryan D Evans
NPI 1558310672
$3,676.56
in general payments reported to CMS, 2019-2025
29 companies · $249 in 2025
The $249 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $334 · 2020: $488 · 2021: $814 · 2022: $667 · 2023: $647 · 2024: $477 · 2025: $249.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,373.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,372.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,260.99 | 2019-2025 | |
| Lilly USA, LLC | $682.37 | 2019-2024 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $277.26 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $212.33 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $160.27 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $139.57 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $98.14 | 2019-2025 | Farxiga, Airsupra |
| Pfizer INC. | $91.31 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $86.63 | 2020-2024 | Xifaxan |
| Glaxosmithkline, LLC. | $85.47 | 2022-2023 | Trelegy Ellipta, Arexvy, Shingrix |
| Astellas Pharma US INC | $76.99 | 2020-2024 | Veozah, Myrbetriq |
| Amgen INC. | $74.11 | 2019-2024 | Repatha, Otezla, Evenity |
| Merck Sharp & Dohme LLC | $56.00 | 2023-2025 | Capvaxive, Gardasil 9, M-M-R II |
| Kowa Pharmaceuticals America, INC. | $48.45 | 2019-2025 | Livalo, Zoryve |
| Sumitomo Pharma America, INC. | $45.89 | 2025 | Gemtesa |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $42.34 | 2024-2025 | Voquezna |
| Janssen Pharmaceuticals, INC | $27.45 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $24.73 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $24.54 | 2022 | |
| Axsome Therapeutics, INC. | $23.76 | 2025 | Sunosi |
| Bayer Healthcare Pharmaceuticals INC. | $22.55 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $21.54 | 2023 | Rexulti |
| Antares Pharma, INC. | $17.55 | 2020 | |
| Ibsa Pharma INC. | $15.69 | 2020 | |
| Biogen, INC. | $13.87 | 2021 | |
| Bausch Health US, LLC | $12.05 | 2021 | |
| Corium, LLC | $12.05 | 2023 | Adlarity |
| Ironwood Pharmaceuticals, INC | $11.54 | 2020 | |
| Amarin Pharma, INC. | $11.12 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryan Evans listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.